Literature DB >> 33981388

Retraction: Oral leukoplakia, a clinical-histopathological study in 412 patients.

Andrea Rubert1, Leticia Bagán2, Jose V Bagán3.   

Abstract

The authors detected some minor errors in the published manuscript (Rubert A, Bagán L, Bagán JV. Oral leukoplakia, a clinical-histopathological study in 412 patients. J Clin Exp Dent. 2020 Jun 1;12(6):e540-e546. doi: 10.4317/jced.57091. PMID: 32665812; PMCID: PMC7335600.) and have requested that the entire article be republished with these errors already rectified.
BACKGROUND: A retrospective clinical-histopathological study was made of the evolution of oral leukoplakia over time, staging the disease according to the classification of van der Waal.
MATERIAL AND METHODS: A study was made of 412 patients with oral leukoplakia, analyzing the corresponding clinical factors and histopathological findings; assessing associations between the different clinical presentations and epithelial dysplasia; and evaluating the factors influencing malignant transformation of the lesions.
RESULTS: Clinically, homogeneous presentations were seen to predominate (n = 336, 81.6%), while histologically most of the lesions exhibited no dysplastic changes (n = 271; 65.7%). Stage 1 of the van der Waal classification was the most common presentation (n = 214; 51.9%). The lesion malignization rate was 8.5%, and the factors associated to a significantly increased malignization risk were non-homogeneous OL lesions (p=0.00), lesion location in the tongue (p=0.00), and the presence of epithelial dysplasia (p=0.00).
CONCLUSIONS: In our series of patients with oral leukoplakia, malignization was associated to the less common clinical presentations of the disease, i.e., non-homogeneous lesions, and the latter tended to exhibit high grade epithelial dysplasia. Key words:Oral leukoplakia, potentially malignant disorders, malignant transformation. Copyright:
© 2021 Medicina Oral S.L.

Entities:  

Year:  2021        PMID: 33981388      PMCID: PMC8106929          DOI: 10.4317/jced.532746

Source DB:  PubMed          Journal:  J Clin Exp Dent        ISSN: 1989-5488


  29 in total

Review 1.  [Oral leukoplakia].

Authors:  M J García-Pola Vallejo; J M García Martín
Journal:  Aten Primaria       Date:  2002-01       Impact factor: 1.137

2.  Tobacco usage in relation to the anatomical site of oral leukoplakia.

Authors:  K P Schepman; P D Bezemer; E H van der Meij; L E Smeele; I van der Waal
Journal:  Oral Dis       Date:  2001-01       Impact factor: 3.511

3.  Prospective study of fruits and vegetables and risk of oral premalignant lesions in men.

Authors:  Nancy Nairi Maserejian; Edward Giovannucci; Bernard Rosner; Athanasios Zavras; Kaumudi Joshipura
Journal:  Am J Epidemiol       Date:  2006-07-17       Impact factor: 4.897

4.  Incidence of oral carcinoma in patients with leukoplakia of the oral mucosa.

Authors:  J Einhorn; J Wersall
Journal:  Cancer       Date:  1967-12       Impact factor: 6.860

5.  Oral leukoplakia and malignant transformation. A follow-up study of 257 patients.

Authors:  S Silverman; M Gorsky; F Lozada
Journal:  Cancer       Date:  1984-02-01       Impact factor: 6.860

Review 6.  Oral cancer and precancerous lesions.

Authors:  Brad W Neville; Terry A Day
Journal:  CA Cancer J Clin       Date:  2002 Jul-Aug       Impact factor: 508.702

Review 7.  Pooled estimate of world leukoplakia prevalence: a systematic review.

Authors:  Stefano Petti
Journal:  Oral Oncol       Date:  2003-12       Impact factor: 5.337

Review 8.  Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics.

Authors:  Jesper Reibel
Journal:  Crit Rev Oral Biol Med       Date:  2003

9.  Follow-up studies in oral leukoplakia.

Authors:  J Bánóczy
Journal:  J Maxillofac Surg       Date:  1977-02

10.  Oral premalignant lesions: epidemiological and clinical analysis in the northern Polish population.

Authors:  Anna Starzyńska; Anita Pawłowska; Dorota Renkielska; Igor Michajłowski; Michał Sobjanek; Izabela Błażewicz
Journal:  Postepy Dermatol Alergol       Date:  2014-12-03       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.